Complimentary Technical Snapshots on Puma Biotech and Three More Biotech Stocks

Stock Research Monitor: PGNX, PLX, and RDUS

LONDON, UK / ACCESSWIRE / June 28, 2018 / If you want a free Stock Review on PBYI sign up now at www.wallstequities.com/registration. For today, WallStEquities.com presents the following stocks for evaluation: Progenics Pharmaceuticals Inc. (NASDAQ: PGNX), Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Puma Biotechnology Inc. (NASDAQ: PBYI), and Radius Health Inc. (NASDAQ: RDUS). These companies are part of the Biotech industry, which broadly segments into the medical and agricultural markets. Although enterprising biotechnology is also being applied to other exciting areas like industrial production of chemicals, and bioremediation, the use in these areas is still specialized and limited. All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Progenics Pharmaceuticals

Shares in New York City, New York-based Progenics Pharmaceuticals Inc. saw a decline of 3.09%, ending Wednesday's trading session at $8.16. The stock recorded a trading volume of 936,961 shares. The Company's shares have gained 8.95% in the last month, 10.72% over the last three months, and 18.26% over the past year. The stock is trading 6.11% and 20.45% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Progenics Pharma, which develops medicines and other technologies to target and treat cancer in the US and internationally, have a Relative Strength Index (RSI) of 50.16.

On June 26th, 2018, Progenics Pharma announced that it has completed enrollment in its Phase-2/3 OSPREY clinical trial evaluating the diagnostic accuracy of its PSMA-targeted PET/CT imaging agent, PyL™ (18F-DCFPyL), in prostate cancer. Get the full research report on PGNX for free by clicking below at:

www.wallstequities.com/registration/?symbol=PGNX

Protalix BioTherapeutics

Karmiel, Israel-based Protalix BioTherapeutics Inc.'s stock declined 2.08%, closing the day at $0.44 with a total trading volume of 159,028 shares. The stock is trading 0.70% below their 50-day moving average. , which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, Shares of the company, which focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally, have an RSI of 45.14.

On June 05th, 2018, Protalix BioTherapeutics announced that additional positive results from the Company's phase II clinical trial of OPRX-106 for the treatment of ulcerative colitis were presented at the Digestive Disease Week® 2018 Annual Meeting. OPRX-106 is a plant cell-expressed recombinant human tumor necrosis factor receptor II fused to an IgG1 Fc domain (TNFRII-Fc) in development for oral administration. Access the free research report on PLX now by signing up at:

www.wallstequities.com/registration/?symbol=PLX

Puma Biotechnology

On Wednesday, shares in Los Angeles, California headquartered Puma Biotechnology Inc. recorded a trading volume of 2.21 million shares, which was higher than their three months average volume of 852,550 shares. The stock ended the day 10.62% lower at $56.80. The Company's shares have advanced 10.08% in the past month. The stock is trading above its 50-day moving average by 0.75%. Furthermore, shares of Puma Biotechnology, which focuses on the development and commercialization of products to enhance cancer care in the US, have an RSI of 53.38.

On June 26th, 2018, Puma Biotechnology announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive trend vote recommending the approval of the Marketing Authorisation Application (MAA) for neratinib for the extended adjuvant treatment of early stage HER2-positive hormone receptor positive breast cancer. The decision follows a reexamination of the negative opinion announced by the CHMP at its formal meeting with the Company to discuss the MAA on February 23rd, 2018. Are you already registered with Wall St. Equities? Do so now for free, and get the report on PBYI at:

www.wallstequities.com/registration/?symbol=PBYI

Radius Health

Waltham, Massachusetts headquartered Radius Health Inc.'s stock dropped 3.46%, finishing yesterday's session at $27.94 with a total trading volume of 514,841 shares. The stock is trading below their 50-day moving average by 9.35%. Shares of the Company, which develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology, have an RSI of 39.52. Aspiring Member, please take a moment to register below for your free research report on RDUS at:

www.wallstequities.com/registration/?symbol=RDUS

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St Equities